Mallinckrodt Sets Out Four Priorities For 2019 And Foresees Specialty Generics Growth

Completing the planned spin-off of its specialty generics and API business into an independent publicly-traded company is one of four priorities that Mallinckrodt has set out for 2019. Despite expecting a “relatively negative” pricing environment this year, chief executive Mark Trudeau believes the Specialty Generics division will achieve growth.